Browse by author
Lookup NU author(s): Professor Julie Irving
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Acute lymphoblastic leukaemia is the most common childhood cancer and for those children who relapse, prognosis is poor and new therapeutic strategies are needed. Recurrent pathways implicated in relapse include RAS, JAK STAT, cell cycle, epigenetic regulation, B cell development, glucocorticoid response, nucleotide metabolism and DNA repair. Targeting these pathways is a rational therapeutic strategy and may deliver novel, targeted therapies into the clinic. Relapse often stems from a minor clone present at diagnosis and thus analysis of persisting leukaemia during upfront therapy may allow targeted drug intervention to prevent relapse.
Author(s): Irving JAE
Publication type: Review
Publication status: Published
Journal: British Journal of Haematology
Print publication date: 01/03/2016
Online publication date: 16/11/2015
Acceptance date: 01/01/1900
ISSN (print): 0007-1048
ISSN (electronic): 1365-2141